Summary of Discussion: Advancing Canada’s Leadership in Vaccine Innovation

This Research Sponsor Advisory (RSA) meeting examined opportunities to strengthen Canada's leadership in vaccine innovation amid a changing global landscape marked by declining investment in vaccine research and development. Discussions focused on accelerating the transition from discovery science to Phase I clinical trials, strengthening Canada's vaccine innovation ecosystem, and building public trust in emerging vaccine technologies. Participants explored scientific, regulatory, economic, and societal factors that influence Canada's capacity to develop, evaluate, manufacture, and implement next-generation vaccines.